Hunt Lawrence, Mike Nicoletti, and Jason Wallace unpack why the Hormuz panic doesn’t hold, where Google’s real AI risk actually lives, and how the PBM business model is unwinding in real time. Get the Cash Flow Memo at telltales.us.

The Cashflow Memo

Key Takeaways

* Hunt’s oil base case holds at $90 (Brent $108 / WTI $104 today) against consensus $150 calls: Saudi Aramco already posted higher March cash flow routing crude to the Red Sea, ADNOC is twinning the Oman→Fujairah line, Iraq/Kuwait are moving barrels by truck-and-pipe through Syria, and Iran loses leverage over time even without a nuclear deal.

* Exhibit A is straining on interest expense (10Y at 4.5% vs. the 3.5% baseline assumption); Mike’s debt/GDP-stabilization-near-100% bet leans on Claude-class AI compressing Medicare/Medicaid spend into flat-to-declining, with defense and interest as the other binding lines.

* Google ran from $162 to $400 in 52 weeks: AI Overviews defused the visible ChatGPT threat, but the real risk is agentic search rewiring monetization (Exa just raised $225M at $2B+ from a16z), and Jason posits a chunk of Google’s incremental search revenue is OpenAI paying for web-index grounding.

* Gemini Spark (I/O) is Google playing innovator’s-dilemma offense, a 24/7 personal agent running across Gmail/Calendar/Drive that no entrant can replicate without Google’s existing data perimeter; the Google + Meta + Amazon ad-network moat remains durable enough that OpenAI is retreating to Anthropic-style subscription revenue.

* PBM pricing power is unwinding in real time: Trump Rx relaunched with Cost Plus Drug + Amazon Fulfillment backends (drugs at ~25% of copay), UNH/OptumRx moving to a transparent flat-fee model and dropping prior auth on 30% of minor procedures, CVS adding biosimilars, and Lilly’s DTC channel proving out, all setting up a healthcare-investment deep dive in two weeks.

Show Notes

[00:00] Welcome to Telltales Mike opens the show and points listeners to this week’s Cash Flow Memo at telltales.us.

[00:18] Disclaimer Standard disclosure.

[00:31] Exhibits A, B, C — Oil, Hormuz, and the Federal Deficit Hunt walks through how Saudi Aramco, ADNOC, Iraq, and Kuwait are routing barrels around Hormuz via Red Sea ports, the Fujairah pipeline, and Syrian truck-and-pipe corridors. Why consensus $150 oil is wrong and Hunt’s $90 base case holds. Closes on interest expense and Medicare/Medicaid as the binding lines on Exhibit A.

[06:52] More than Moats: Google Hunt frames Alphabet as the latest More than Moats target after Lilly, Nvidia, Goldman, and Microsoft. Mike and Jason work through the antitrust outcome (Chrome retained, web-index data opened to competitors), AI Overviews defending low-intent queries, and the real risk: agentic search and Exa’s $225M raise.

[13:04] Google I/O and Gemini Spark Jason walks through I/O announcements including the new content-credentialing system and Gemini Spark, Google’s always-on personal agent running across Gmail, Calendar, and Drive. Why no entrant can replicate this without Google’s existing data perimeter.

[15:34] The Advertising Moat Hunt frames Google + Meta + Amazon as a durable ad-network oligopoly. Why OpenAI’s billion-user advertising thesis is failing and the pivot back to Anthropic-style subscription revenue.

[19:53] Healthcare: PBMs, Trump Rx, and Lilly DTC Jason walks through Bill Cassidy’s primary loss, Trump Rx’s relaunch on Cost Plus Drug and Amazon Fulfillment rails, CVS adding biosimilars, OptumRx moving to a transparent flat-fee PBM model, UnitedHealth dropping prior auth on 30% of minor procedures, and Eli Lilly’s working DTC channel.

[23:50] Fixing the Premium Side Hunt asks how to bring the same rationalization to monthly health insurance premiums. Mike on diagnostic-monitoring opt-in plans with discounted premiums; Hunt on quarterly rebate structures that reward healthier behavior. Why emergency care is the structural hard problem.

[29:33] Healthcare Investment Ideas — Two-Week Prep Hunt commits the team to identifying three or four entities running rational healthcare models that could be good investments. Surprise topic next Wednesday; healthcare deep dive in two weeks.

[30:38] Sign-Off Stay healthy, back next Wednesday.

Subscribe wherever you listen, and grab the Cash Flow Memo at telltales.us.

Cashtags

$GOOGL $AMZN $AAPL $MSFT $NVDA $META $CVS $LLY $UNH $GS

This post and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com